Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration
Mechanisms of Ageing and Development · 2026
DOI: 10.1016/j.mad.2026.112161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mechanisms of Ageing and Development, 2026. Verfasst von Mehdi Alami und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Raltegravir Potassium, Peptide Fragments, Alzheimer Disease. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Alzheimer Society of Canada.
Themen: Demenz
Abstract (Originalsprache)
There is growing evidence supporting the potential role of microbial infections in the aetiology of Alzheimer's disease (AD) and the protective role of anti-viral therapies. However, not much is known about the molecular mechanisms underlying their effects. We aimed to explore the modulatory role of raltegravir on monomeric amyloid beta 1-42 (m-Aβ1-42)-induced molecular alterations in cellular models of AD. Here we show, using the flow cytometry technique combined with specific monoclonal antibodies, that raltegravir significantly abolishes the m-Aβ1-42-stimulating effect on p-tau 181, and that this effect involves the upregulation of PP2Aα+ β. This effect does not appear to be mediated by GSK-3β and CdK5 modulation, since no significant effect was observed on these kinases. Furthermore, raltegravir treatment significantly reduced CD86 expression without any impact on CD163, suggesting a possible affinity towards reducing the microglia M1-phenotype rather than improving the M2 state. Additionally, raltegravir significantly attenuated IL-1β production, likely through the downregulation of the NLRP3-inflammasome signaling pathway, indicating an important anti-inflammatory activity. Collectively, our in vitro findings are preliminary mechanistic observations that support raltegravir's repurposing for AD, thus soliciting further complementary research, especially in relevant animal models of AD, to accelerate the translation of these findings into the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada.
- University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada; Sultan Moulay Sliman University, Polydisciplinary Faculty, Department of Biology, Be…
- University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada; Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, M…
- Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco.
- Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Izumi Biosciences, Inc., Lexington, MA, USA.
Förderung
- Canadian Institutes of Health Research
- Alzheimer Society of Canada
Zitieren
APA
Alami, M., Berrougui, H., Boumezough, K., Salih, I., Sadki, K., Laurent, B., van Tellingen, O., Bunt, T., Khalil, A., & Fulop, T. (2026). Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration. Mechanisms of Ageing and Development. https://doi.org/10.1016/j.mad.2026.112161
Vancouver
Alami M, Berrougui H, Boumezough K, Salih I, Sadki K, Laurent B, et al. Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration. Mechanisms of Ageing and Development. 2026. doi:10.1016/j.mad.2026.112161
BibTeX
@article{Alami2026,
author = {Alami, Mehdi and Berrougui, Hicham and Boumezough, Kaoutar and Salih, Ikram and Sadki, Khalid and Laurent, Benoit and van Tellingen, Olaf and Bunt, Ton and Khalil, Abdelouahed and Fulop, Tamas},
title = {Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration},
journal = {Mechanisms of Ageing and Development},
year = {2026},
doi = {10.1016/j.mad.2026.112161}
}
EUVIMED